Copyright 1998 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.1998
The recent review by Salcedo and Al-Kawas1 may cause confusion in the minds of many physicians. The European Helicobacter pylori Study Group and the 1997 International Update Conference organized under the auspices of the American Digestive Health Foundation both recommended specific combination drug regimens against H pylori infection.2,3 Appropriate eradication rates are considered to be ≥ 90% or higher on a per-protocol analysis and ≥ 80% or higher on an intent-to-treat analysis.2 Many of the regimens reviewed by Salcedo and Al-Kawas fail to meet these goals and do not deserve further consideration; there is no point in educating physicians about inadequate or obsolete therapies except to stress that they should be avoided.
Howden CW, Hunt RH. Treating Helicobacter pylori. Arch Intern Med. 1998;158(21):2396-2398. doi: